Talking Points

Episodes page 3 of 5

1. Episode 161: AMULET-IDE: One-Year Outcomes

   9 Nov 2022 · 6:45

   C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.

2. Episode 160: Shock Classification Gets an Update

   2 Nov 2022 · 4:06

   C. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.

3. Episode 159: MICHELLE: Rivaroxaban in COVID-19

   19 Oct 2022 · 7:37

   C. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.

4. Episode 158: The RIPCORD 2 Trial

   5 Oct 2022 · 11 min

   C. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.

5. Episode 157: PARTNER 3: Two-Year Economic Outcomes

   14 Sep 2022 · 4:33

   C. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.

6. Episode 156: The IAMI Trial

   7 Sep 2022 · 8:19

   C. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.

7. Episode 155: Two DCBs Go Head to Head in De Novo CAD

   25 Aug 2022 · 12 min

   C. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.

8. Episode 154: The EMPEROR-Preserved Trial

   10 Aug 2022 · 5:14

   C. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.

9. Episode 153: iFR-SWEDEHEART at 5 Years

   3 Aug 2022 · 6:30

   C. Michael Gibson and Matthias Götberg review 5-year findings after iFR- versus FFR-guided PCI.

10. Episode 152: PRONOUNCE: Prostate Cancer Drugs and CVD

    20 Jul 2022 · 10 min

    Renato Lopes and C. Michael Gibson discuss PRONOUNCE comparing the cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and CVD.

11. Episode 151: Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk

    6 Jul 2022 · 9:01

    Desai and Anahita Dua discuss highlights from a CME program on reducing thrombosis risks in patients with PAD post-revascularization. Claim credit: https://bit.ly/3QTpBt6. Supported by an educational grant from Janssen…

12. Episode 150: The TOMAHAWK Trial

    6 Jul 2022 · 4:26

    C. Michael Gibson and Steffen Desch discuss whether immediate angiography is warranted after out-of-hospital cardiac arrest.

13. Episode 149: The OPTIMUM Trial

    22 Jun 2022 · 5:23

    C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.

14. Episode 148: The MASTER DAPT Trial

    8 Jun 2022 · 9:00

    C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.

15. Episode 147: The EROSION III Trial

    1 Jun 2022 · 12 min

    C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.

16. Episode 146: The LIFE Trial

    18 May 2022 · 8:15

    C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.

17. Episode 145: PRAGUE 17: LAA Closure vs DOACs

    4 May 2022 · 12 min

    C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.

18. Episode 144: MASTER DAPT: High-Risk Patients

    20 Apr 2022 · 6:49

    C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.

19. Episode 143: The ADAPTABLE Study: Patient-Centered Aspirin

    6 Apr 2022 · 14 min

    C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.

20. Episode 142: ISCHEMIA: Complete Revascularization and QoL

    23 Mar 2022 · 6:38

    C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.

21. Episode 141: The STRENGTH Study of Omega-3s

    16 Mar 2022 · 13 min

    C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.

22. Episode 140: The SWISS-APERO Trial

    2 Mar 2022 · 4:03

    C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.

23. Episode 139: The 2021 ESC HF Guidelines

    9 Feb 2022 · 11 min

    C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.

24. Episode 138: The ATLANTIS Trial: DOACs in TAVI?

    2 Feb 2022 · 15 min

    C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.

25. Episode 137: Early Intrepid TMVR Results

    12 Jan 2022 · 6:10

    C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.

26. Episode 136: Two DCBs vs POBA in Coronary In-Stent Restenosis

    5 Jan 2022 · 6:13

    C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.

27. Episode 135: The ULTIMATE Trial

    22 Dec 2021 · 5:52

    Junjie Zhang and C. Michael Gibson discuss 3-year outcomes after IVUS- versus angiography-guided DES implantation.

28. Episode 134: The PROSPECT ABSORB Trial

    8 Dec 2021 · 13 min

    Gregg Stone and C. Michael Gibson discuss a randomized trial examining interventional treatment of vulnerable plaques.

29. Episode 133: The COBRA-REDUCE Trial

    2 Dec 2021 · 9:25

    Robert Byrne and C. Michael Gibson discuss a randomized trial of a thromboresistant Polyzene F-coated stent with 14-day DAPT in high-bleeding-risk patients.

30. Episode 132: The RIVER Trial

    10 Nov 2021 · 8:58

    Otavio Berwanger and C. Michael Gibson discuss rivaroxaban versus warfarin in patients with bioprosthetic mitral valves and atrial fibrillation or flutter.

31. Episode 131: The SCOPE II Trial

    3 Nov 2021 · 10 min

    Corrado Tamburino and C. Michael Gibson discuss a randomized trial of two self-expanding TAVR bioprostheses.

32. Episode 130: The DISRUPT CAD III Trial

    20 Oct 2021 · 17 min

    Dean Kereiakes and C. Michael Gibson discuss intravascular lithotripsy for the treatment of severe coronary calcification.

33. Episode 129: The TICO-STEMI Trial

    6 Oct 2021 · 8:04

    Byeong-Keuk Kim and C. Michael Gibson discuss a randomized trial of ticagrelor monotherapy versus ticagrelor with aspirin in STEMI.

34. Episode 128: The COMPARE CRUSH Trial

    22 Sep 2021 · 9:51

    Georgios Vlachojannis and C. Michael Gibson discuss a randomized trial of prehospital crushed versus uncrushed prasugrel in STEMI.

35. Episode 127: The SOLOIST-WHF and SCORED Trials

    8 Sep 2021 · 17 min

    Deepak Bhatt and C. Michael Gibson discuss data on sotagliflozin in diabetes.

36. Episode 126: The REFLECT II Trial

    25 Aug 2021 · 8:05

    Jeffrey Moses and C. Michael Gibson discuss a randomized trial of cerebral embolic protection during TAVR.

37. Episode 125: The TIPS-3 Trial

    18 Aug 2021 · 9:21

    Salim Yusuf and C. Michael Gibson discuss aspirin alone and in combination with a polypill for CVD primary prevention.

38. Episode 124: The MITHRAS Trial

    4 Aug 2021 · 3:37

    Philipp Lurz and C. Michael Gibson discuss a randomized trial of ASD closure after TMVr.

39. Episode 123: The XIENCE 90/28 Trial

    21 Jul 2021 · 11 min

    Roxana Mehran and C. Michael Gibson discuss 3-month and 1-month DAPT after everolimus-eluting stents in high-bleeding-risk patients.

40. Episode 122: The MSTOPS Trial

    7 Jul 2021 · 6:49

    Steven Steinhubl and C. Michael Gibson discuss 3-year outcomes in a nationwide, randomized, pragmatic clinical trial of A-fib screening.

41. Episode 121: The TARGET FFR Trial

    23 Jun 2021 · 8:04

    Damien Collison and C. Michael Gibson discuss a randomized trial of physiology-guided PCI optimization.

42. Episode 120: The STRENGTH Trial

    16 Jun 2021 · 12 min

    A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.

43. Episode 119: The STRENGTH Trial

    2 Jun 2021 · 12 min

    A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.

44. Episode 118: The OPTIMIZE Trial

    19 May 2021 · 11 min

    Dean Kereiakes and C. MIchael Gibson discuss a randomized trial of a novel, ultra-low-profile fixed-wire DES.

45. Episode 117: The AHA COVID-19 CVD Registry

    6 May 2021 · 16 min

    Robert Harrington and C. Michael Gibson discuss the registry's design, implementation, and initial results.

46. Episode 116: The TANGO Trial

    21 Apr 2021 · 6:49

    Ehrin Armstrong and C. Michael Gibson discuss a randomized, dose-escalation trial of temsirolimus adventitial delivery below the knee.

47. Episode 115: The GALACTIC-HF Trial

    7 Apr 2021 · 14 min

    John Teerlink and C. Michael Gibson discuss omecamtiv mecarbil in chronic HFrEF.

48. Episode 114: The NACMI COVID-19 Registry

    24 Mar 2021 · 28 min

    Timothy Henry and C. Michael Gibson discuss outcomes from the North American registry.

49. Episode 113: The EXPLORER-HCM Trial

    17 Mar 2021 · 11 min

    Iacopo Olivotto and C. Michael Gibson discuss mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.

50. Episode 112: FLASH Registry: Acute Hemodynamic Improvement

    3 Mar 2021 · 6:26

    C. Michael Gibson and Catalin Toma discuss acute hemodynamic improvement with percutaneous mechanical thrombectomy in a real-world pulmonary embolism population.